<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745780</url>
  </required_header>
  <id_info>
    <org_study_id>MYO_DCI_GYM_DIABETES</org_study_id>
    <nct_id>NCT04745780</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects Diabetic Patients.</brief_title>
  <acronym>MYDIAGYM</acronym>
  <official_title>Randomized, Controlled, Open-label Study to Evaluate the Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects With Type 2 Mellitus Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lo.Li.Pharma s.r.l</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mellitus type 2 diabetes (T2MD) is a chronic disease characterized by high glucose plasmatic&#xD;
      level due to an alteration of insulin function. Several authors have correlated this altered&#xD;
      function to an inositol depletion. The main present member of inositol family in biological&#xD;
      systems is undoubtedly myo-inositol, a precursor of several second messengers, widely&#xD;
      involved in insulin signalling. For this reason this molecule is considered an&#xD;
      insulin-sensitizer. The high excretion of inositol in T2MD patients is frequent, inducing a&#xD;
      myo-inositol depleted state that favours the onset of insulin resistance, impairing the&#xD;
      activity of this hormone. The aim of this study is to evaluate the efficacy and the safety of&#xD;
      a food supplement containing myo-inositol in T2MD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>up to 6 months of treatment</time_frame>
    <description>Variation of glycated hemoglobin level (HbA1c) after 3 and 6 months in comparison to baseline detected in the blood - %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemia</measure>
    <time_frame>At baseline and 3 and 6 months of treatment</time_frame>
    <description>Variation of fasting blood sugar level after 3 and 6 months in comparison to baseline detected in the blood - mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>At baseline and 3 and 6 months of treatment</time_frame>
    <description>Variation of cholesterol level (Total, HDL and LDL) after 3 and 6 months in comparison to baseline detected in the blood - mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>At baseline and 3 and 6 months of treatment</time_frame>
    <description>Number of hypoglycemic events (&lt; 70 mg/dl) and severe hypoglycemic events (&lt; 54 mg/dl) during the study (6 months) - Number of events (n)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with a formulation containing Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treated with Placebo - Two-times daily on an empty stomach, for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin</intervention_name>
    <description>Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - Two-times daily on an empty stomach, for 6 months</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With diagnosis of Type 2 Mellitus Diabetes for at least 1 year&#xD;
&#xD;
          -  Levels of Hb1Ac ranging from 7.5% to 9.0%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that require insulin treatment&#xD;
&#xD;
          -  Treated at baseline with food supplements or drugs containing Myo-inositol,&#xD;
             D-chiro-inositol, alphalactalbumin, zinc, or Gymnema Sylvestre;&#xD;
&#xD;
          -  Any contraindications to the treatment or to any substance used for the treatment&#xD;
&#xD;
          -  Subjects with intestinal malabsorption&#xD;
&#xD;
          -  Patients subjected to surgery within 6 months before baseline;&#xD;
&#xD;
          -  Chronic treatment with systemic corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Basilio Pintaudi</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Basilio Pintaudi, MD</last_name>
      <phone>0039 026444</phone>
      <phone_ext>2464</phone_ext>
      <email>basilio.pintaudi@ospedaleniguarda.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Myo-inositol</keyword>
  <keyword>Gymnema sylvestre</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

